# Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

> **NCT03341845** · PHASE2 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 40 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03341845
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-28
- **Primary completion:** 2023-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03341845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03341845, "Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03341845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*